Lantheus announced a definitive merger agreement with Curium under which Curium will acquire the company for $102.50 per share in cash plus a non-transferable contingent value right (CVR) of up to $12.00 per share tied to future sales milestones. The take-private deal is subject to shareholder approval and regulatory clearances and is not conditioned on financing. A separate CVR Agreement to be executed at or before closing sets milestones across Lantheus’ prostate cancer, neurology and DEFINITY franchises through fiscal year 2030.
Agreement 1: Lantheus to Be Acquired by Curium for $102.50 Cash Plus Up to $12.00 CVR
- Agreement type: Agreement and Plan of Merger
- Counterparty: Curium US Holdings
- Signed / Effective: Aug 03 2026 / N/A
- Duration / Termination: N/A
- Reason: Take-private sale to Curium with CVR tied to sales milestones
Agreement 2: Lantheus Shareholders to Receive Non-Transferable CVRs Worth Up to $12 on Milestones
- Agreement type: Contingent Value Rights Agreement
- Counterparty: Curium US Holdings and Rights Agent
- Signed / Effective: N/A / N/A
- Duration / Termination: Through FY2030 milestones
- Reason: Provide additional consideration tied to franchise performance
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.